Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Novartis’ Sandoz division announces antibiotic manufacturing plan

Novartis’ Sandoz division announces antibiotic manufacturing plan

Joint investment agreed with the Austrian federal government. Novartis’ generics division Sandoz has announced plans for a joint investment to strengthen the long-term future of integrated antibiotics manufacturing in Europe. ... Novartis is committed

GSK’s anti-BCMA drug leads crowded CHMP recommendations

GSK’s anti-BCMA drug leads crowded CHMP recommendations Among other highlights from the meeting, Novartis scored a recommendation for its sickle cell therapy Adakveo (crizanlizumab) for the prevention of recurrent vaso-occlusive crises or pain crises, while Kyowa Kirin

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma Company aims to extend market reach. Biogen has announced it will test its spinal muscular atrophy drug Spinraza in patients who still have unmet clinical needs after treatment with Novartis’ gene ... Novartis’ gene therapy was approved to treat SMA

Roche cites COVID-19 and biosimilars in Q2 decline

Roche cites COVID-19 and biosimilars in Q2 decline But we now see clear signs of recovery,” he added. Earlier this week, Novartis reported a decline in its second quarter results, with that decrease also attributed to the negative impact

Merck, Bayer get FDA priority review for heart failure drug

Merck, Bayer get FDA priority review for heart failure drug That includes Novartis’ Entresto (sacubitril/valsartan), which demonstrated 20% overall reduction in deaths or hospitalisations, and AstraZeneca’s Farxiga/Forxiga (dapagliflozin) which had a 26% improvement in cardiovascular death and worsening

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
...
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics